en.Wedoany.com Reported - Sovereign AI company Cohere of Canada announced on May 19 the official completion of its acquisition of Reliant AI, a biopharma AI company. Reliant AI has operational bases in Montreal and Berlin. This transaction integrates Reliant AI's R&D team, proprietary biomedical datasets, and vertical domain technologies entirely into Cohere's enterprise-grade sovereign AI platform, significantly expanding Cohere's business footprint in the global healthcare and life sciences sectors. These two industries have extremely high requirements for security, data privacy, and regulatory compliance.
Aidan Gomez, Co-founder and CEO of Cohere, stated: "We are thrilled to welcome the Reliant AI team. Healthcare is one of the most impactful application areas for AI, and it requires secure, sovereign, and domain-specific systems. Building on our shared roots in Canada and Germany, we will accelerate progress in this critical field. North for Pharma will become a core product within Cohere's growing portfolio of industry AI solutions." Following the transaction, Reliant AI's existing customer relationships—including GSK, Medicus Pharma, and Kyowa Kirin—will be taken over and continuously advanced by Cohere.
Reliant AI's flagship product is an intelligent research platform already used by global biopharma organizations for automating systematic literature reviews, competitive landscape analysis, and the extraction of unstructured scientific and regulatory data. The platform can also rapidly identify therapeutic precedents and model market feasibility, significantly compressing decision-making and time-to-market cycles. Reliant AI was founded in 2023 by Karl Moritz Hermann, Richard Schlegel, and Marc G. Bellemare. With the completion of this acquisition, Karl Moritz Hermann will assume the role of Vice President of AI Verticalization at Cohere's Berlin office, and Marc Bellemare will serve as Vice President of Modeling at the Montreal office.
Cohere will accelerate the development of North for Pharma, an agentic AI system purpose-built for the biopharma industry, designed to enhance the productivity and efficiency of R&D, clinical development, and scientific analysis teams. North for Pharma further expands Cohere's North product suite for regulated industries, which previously covered the financial services and telecommunications sectors. By integrating Reliant AI's capabilities, Cohere can introduce specialized AI models and solutions into pharmaceutical and biotechnology workflows, addressing specialized challenges that general-purpose AI cannot handle.
Founded in 2019 and headquartered in Toronto, Cohere was established by former Google researchers and is currently a benchmark enterprise in the global sovereign AI sector. The company adopts a strategy of customizing and deploying smaller-scale, highly specialized large language models for specific business scenarios, distinctly differentiating itself from the "general-purpose giant model" approach championed by competitors like OpenAI. Reliant AI's clients include global leading pharmaceutical companies such as British pharma giant GSK, France's Ipsen, and Japan's Kyowa Kirin.
This acquisition comes just weeks after Cohere announced the merger with German enterprise AI solution provider Aleph Alpha, clearly signaling an accelerated push in its sovereign AI strategy. Joelle Pineau, Chief AI Officer at Cohere, noted in an interview that the company has successfully launched AI tools for general enterprise functions like human resources, finance, and communications, while the Reliant AI team possesses experience in both building AI models and products, which is precisely what made it an attractive acquisition target. She emphasized that there are enormous opportunities in the direction of industry verticalization. Cohere has raised a total of $1.6 billion to date and is currently conducting a new funding round, with Aleph Alpha's major investor, Schwarz Group, having committed to participate. The financial terms of this acquisition were not disclosed.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
